NEWS

  • A PHASE I STUDY OF XL019, A SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

    This is an abstract that was presented at ASH’s annual meeting on Sunday, December 7, 2008: 4:45 PM 304-306-308 – South (Moscone Center) JAK2 V617F has been identified as a constitutive activating mutation in approximately half of patients with myelofibrosis (MF). MF, a myeloproliferative disorder comprised of primary myelofibrosis and the clinically indistinguishable entities of… Read More »A PHASE I STUDY OF XL019, A SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

    READ MORE

    PANOBINOSTAT MF TRIALS PHASE I

    Drs. Ron Hoffman and John Mascerenhas of Mt. Sinai School of Medicine in New York have reported positive outcomes from their Phase I trial of panobinostat in myelofibrosis patients. Their article published in the British Journal of Haematology states that significant improvement occurred for patients on low dosages of Panobinostat. Click here for the full… Read More »PANOBINOSTAT MF TRIALS PHASE I

    READ MORE

    DR. LAURA MICHAELIS DISCUSSES ISSUES FOR PV AND ET WITH MPN ADVOCACY AND EDUCATION INTERNATIONAL

    Dr. Laura Michaelis of Loyola recently contributed to the MPN Advocacy and Education International’s site to educate people on special issues related to Polycythemia Vera and Essential Thrombocythemia. Dr. Michaelis, who co-chairs the MPN Chicago Roundtable, covers topics such as hormone supplements, surgery risks, venous clotting and more. Click here to read the full article.

    READ MORE

    MPN NEWS FROM ASCO 2013

    June 13, 2013 By Robert Rosen The American Society of Clinical Oncologist just wrapped up its annual meeting in Chicago last week. The meeting brought together over 25,000 oncology professionals from all disciplines. Added to the fertile mix were drug companies, advocacy folks and journalists striving to understand what’s new in cancer research and treatment.… Read More »MPN NEWS FROM ASCO 2013

    READ MORE

    MF CHALLENGE REVIEW MEETING

    June 13, 2013 On June 1, 2013, the MPN Research Foundation and the Leukemia & Lymphoma Society brought together 13 researchers from within and outside the MPNs to review the 2nd round of MF Challenge grant proposals. The meeting was held in a conference space within Northwestern in downtown Chicago where the feasibility, innovative quality… Read More »MF CHALLENGE REVIEW MEETING

    READ MORE

    NEW DATA ON USE OF PEGASYS FOR POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA

    June 20, 2013 Past MPN Research Foundation grantees Srdan Verstovsek and Ross Levine contributed to a paper recently published by the American Society of Hematology which reports on a study of PV and ET patients treated with pegylated interferon alpha-2a, commonly known as Pegasys. Click here for the abstract and to read the full study. Pegasys is… Read More »NEW DATA ON USE OF PEGASYS FOR POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA

    READ MORE

    MF CHALLENGE GRANTS FOR 2013

    7-1-2013 The MPN Research Foundation and the Leukemia & Lymphoma Society are proud to announce the winners of the second round of the MF Challenge grant program. Winners of these one year concept grants focusing on fibrosis and myelofibrosis are:  John Varga and Jonathan Licht (Northwestern University)  Golam Mohi (State University of New York)  Emmanuele… Read More »MF CHALLENGE GRANTS FOR 2013

    READ MORE

    NEW MPN QUARTERLY JOURNAL LAUNCHED

    July 3, 2013 Recently the MPN Forum launched a new quarterly journal focused on scientific medical advances. The idea behind The MPNforum Quarterly Journal (MQJ) is to provide hematologists and scientists a professional forum to talk with other physicians and interested patients in plain English about diagnosis and treatment of myeloproliferative neoplasms. The first issue features a… Read More »NEW MPN QUARTERLY JOURNAL LAUNCHED

    READ MORE

    NEW PREVALENCE DATA FOR MPNS

    A new study by Mayo Clinic, Boston University School of Public Health, and the pharmaceutical company Sanofi’s department of Global Evidence & Value Development has found the prevalence of MPN patients living in the United States to be much higher than previously assumed. They recently concluded a study which used two major insurance claims databases… Read More »NEW PREVALENCE DATA FOR MPNS

    READ MORE

    NEJM LETTER RAISES CONCERN ABOUT PML AND JAKAFI

    July 15, 2013 Recently the New England Journal of Medicine ran a letter to the editor drawing attention to a case in which an MF patient on Jakafi suffered an incidence of progressive multifocal leukoencephalopathy (PML) after starting therapy. Click here for full article Research is ongoing as to whether this is an isolated incident… Read More »NEJM LETTER RAISES CONCERN ABOUT PML AND JAKAFI

    READ MORE

    1 2 3 4 5 38
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?